Hemodynamic changes induced by cardiac angiography with ioxaglate: Comparison with diatrizoate

• Published in: Journal of the American College of Cardiology 1983-11, Vol.2 (5), p.954-957
• Main Authors: Hirshfeld, John W., Laskey, Warren, Martin, Jack L., Groh, William C., Untereker, William, Wolf, Gerald L.
• Format: Article
• Language: English
• Subjects: Adult; Cardiac Catheterization - methods; Contrast Media - adverse effects; Coronary Angiography; Diatrizoate - adverse effects; Drug Evaluation; Heart Ventricles - diagnostic imaging; Hemodynamics - drug effects; Humans; Iodobenzoates - adverse effects; Ioxaglic Acid; Time Factors; Triiodobenzoic Acids - adverse effects
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/S0735-1097(83)80245-9

The hemodynamic and electrocardiographic changes induced by left ventriculography and coronary arteriography with ioxaglate (a new low osmolality angiographic contrast agent) were characterized and compared with the changes induced by a commercial formulation of the commonly used angiographic contrast agent, diatrizoate (Renografin-76). Left ventriculography and coronary arteriography were performed in 25 patients utilizing ioxaglate and in another 25 patients utilizing diatrizoate. Both agents increased left ventricular end-diastolic pressure and decreased arteriovenous oxygen difference after left ventriculography, but the magnitude of the increase caused by ioxaglate was significantly less than that caused by diatrizoate (changes in left ventricular end-diastolic pressure was 5.3 ±1.3 mm Hg with ioxaglate and 9.5 ± 1.5 mm Hg with diatrizoate [p < 0.02]). Change in arteriovenous oxygen difference was -0.33 ± 0.19 ml/100 ml with ioxaglate and -0.85 ± 0.13 ml/100 ml with diatrizoate (p < 0.05). Both agents were well tolerated when used for coronary arteriography with no adverse events occurring in either group. Ioxaglate is a well tolerated cardiac angiographic contrast agent that produces less hemodynamic disturbance than diatrizoate. Accordingly, it may be particularly well suited to use in patients with impaired left ventricular function.